Certara, Inc. CERT
- Market cap
- $1.4B
- P/E
- 0.0×
Follow CERT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 29.70 | 23.75 | 10.60 | 11.81 | 9.41 | 8.03 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 41.79 | 45.48 | 29.04 | 24.96 | 19.87 | 15.69 |
High Price
|
|||
| — | — | — | 899 | 903 | 1,114 | 1,204 | 1,391 | 1,546 | 1,576 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 164 | 209 | 244 | 286 | 336 | 354 | 385 | 419 |
Revenue
|
|||
| — | — | 56.61% | 61.74% | 58.62% | 60.99% | 60.50% | 60.20% | 59.88% | 61.53% |
Gross Margin
|
|||
| — | — | (33) | (9) | (50) | (3) | 19 | (55) | (17) | 8 |
EBT
|
|||
| — | — | (19.89%) | (4.39%) | (20.61%) | (1.18%) | 5.59% | (15.56%) | (4.46%) | 1.82% |
EBT Margin
|
|||
| — | 0 | (33) | (9) | (49) | (13) | 15 | (55) | (12) | (2) |
Net Income
|
|||
| — | — | 39 | 43 | 44 | 47 | 54 | 105 | 69 | 76 |
Depreciation
|
|||
| — | — | 1.24 | 1.57 | 1.83 | 1.91 | 2.14 | 2.23 | 2.40 | 2.61 |
Revenue/Sh
|
|||
| — | — | (0.25) | (0.07) | (0.37) | (0.09) | 0.09 | (0.35) | (0.08) | (0.01) |
Earnings/Sh
|
|||
| — | — | 0.09 | 0.29 | 0.34 | 0.40 | 0.59 | 0.52 | 0.50 | 0.60 |
Cash Flow/Sh
|
|||
| — | — | (0.09) | (0.07) | (0.06) | (0.06) | (0.08) | (0.10) | (0.13) | (0.17) |
Capex/Sh
|
|||
| — | — | 0.00 | 0.22 | 0.28 | 0.34 | 0.51 | 0.42 | 0.37 | 0.44 |
Free CF/Sh
|
|||
| — | — | 3.72 | 3.72 | 6.17 | 6.95 | 6.88 | 6.59 | 6.60 | 6.63 |
Book Value/Sh
|
|||
| — | — | 132 | 132 | 133 | 150 | 157 | 159 | 160 | 160 |
Shares
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 161.75 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | 0.00 | 0.00 | 18.45 | 14.88 | 7.59 | 7.78 | 4.44 | 3.37 |
PS Ratio
|
|||
| — | — | 10.13 | 10.13 | 5.47 | 4.09 | 2.36 | 2.63 | 1.61 | 1.33 |
PB Ratio
|
|||
| — | — | 0.00 | 0.00 | 18.55 | 15.26 | 7.75 | 7.94 | 4.74 | 3.62 |
EV/Sales
|
|||
| — | — | 119.28 | 119.28 | 122.54 | 84.81 | 32.51 | 41.69 | 30.70 | 21.74 |
EV/FCF
|
|||
| — | — | 12 | 38 | 45 | 60 | 93 | 83 | 80 | 96 |
Op' Cash Flow
|
|||
| — | — | (11) | (10) | (8) | (9) | (13) | (15) | (21) | (27) |
Capex
|
|||
| — | — | 0 | 29 | 37 | 51 | 80 | 67 | 59 | 70 |
FCF
|
|||
| — | — | 3 | 25 | 271 | 183 | 239 | 210 | 165 | 162 |
Working Cap'
|
|||
| — | — | 408 | 401 | 299 | 295 | 293 | 291 | 295 | 293 |
Total Debt
|
|||
| — | — | 396 | 372 | 25 | 108 | 53 | 56 | 116 | 104 |
Net Debt
|
|||
| — | — | 493 | 492 | 822 | 1,042 | 1,080 | 1,047 | 1,059 | 1,063 |
Sh' Equity
|
|||
| — | — | (6.33%) | (0.85%) | (4.28%) | (0.95%) | 0.96% | (3.53%) | (0.77%) | (0.10%) |
ROA
|
|||
| — | — | (0.33%) | 1.42% | (1.80%) | 0.74% | 1.79% | (2.31%) | (0.09%) | 1.13% |
ROIC
|
|||
| — | — | (6.75%) | (1.81%) | (7.52%) | (1.42%) | 1.39% | (5.21%) | (1.14%) | (0.15%) |
ROE
|
|||
Certara, Inc. peers in Health Information Services
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| OMCL Omnicell, Inc. | $1.5B | 39.5× | Compare |
| OMDA Omada Health, Inc. | $1.2B | 281× | Compare |
| GDRX GoodRx Holdings, Inc. | $1.2B | 62.5× | Compare |
| TDOC Teladoc Health, Inc. | $1.1B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| HSTM HealthStream, Inc. | $883.3M | 40.5× | Compare |
| SDGR Schrodinger, Inc. | $2.2B | 0.0× | Compare |
| PRVA Privia Health Group, Inc. | $2.5B | 89.6× | Compare |
| SOPH SOPHiA GENETICS SA | $703.2M | 0.0× | Compare |
Certara, Inc. (CERT) key facts
- Certara, Inc. (CERT) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
- Certara, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $418.8 million, up 8.75% from fiscal 2024.
- Certara, Inc. reported a net loss of $1.6 million, or a loss of $0.01 per share, for fiscal 2025.
- As of September 25, 2026, CERT traded at $9.11, a market capitalization of $1.4 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 3.3× sales.
- Return on equity was −0.15% and debt-to-equity 0.30.
Certara, Inc. (CERT) Latest News
14 Sep
Certara cuts jobs while shifting resources to expand its software business for long-term growth. Job cuts combined with software investment represent a major strategic pivot that can reshape cost structure and competitive focus.
6 Aug
Certara posted a wider Q2 loss and executed a leadership shake-up that may undermine its prior bullish outlook. Wider quarterly loss plus executive turnover creates short-term pressure on financials and strategy without guaranteed long-term trajectory shift.
4 Aug
Certara (CERT) held Q2 2026 earnings call discussing financial results, operations and outlook. Quarterly earnings calls disclose performance data that can shift near-term investor views.
Certara, Inc. held its Q2 2026 earnings call covering quarterly financial results and business outlook. Earnings call delivers updated financial metrics and guidance that can shift near-term investor sentiment.
Certara held its Q2 earnings call, presenting financial results, operational updates, and forward guidance for the company. Q2 earnings details and guidance typically affect near-term market sentiment without shifting long-term strategy.
Certara, Inc. reported its second quarter 2026 financial results. Quarterly financial results release supplies performance data that can shift near-term investor views and valuation models.
8 Jul
Certara partners with NVIDIA to integrate AI chips into drug development, enabling advanced simulations and modeling that accelerate pharmaceutical research and innovation. NVIDIA partnership introduces transformative AI technology directly into Certara core drug development services with potential to reshape competitive positioning.
7 Jul
Certara, Inc. (CERT) partners with Nvidia to integrate BioNeMo toolkit, enhancing its AI platform for biosimulation and drug development applications. Nvidia partnership to upgrade AI platform delivers major strategic boost to Certara's biosimulation capabilities and market position.
Certara integrates NVIDIA BioNeMo Agent Toolkit to accelerate drug discovery and development using advanced AI capabilities. NVIDIA BioNeMo integration strengthens Certara AI-driven drug development platform and competitive edge.
7 Jun
Certara outlined AI advancement plans, cost-cutting measures and new growth initiatives at the Jefferies Conference. AI initiatives, cost reductions and new growth engines represent major strategic moves likely to alter company trajectory and investor sentiment.
12 May
Certara, Inc. held its Q1 2026 earnings call, covering financial results and business updates. Quarterly earnings calls typically provide moderate updates on performance without major strategic shifts.
Certara Inc (CERT) Q1 2026 earnings call highlights modest growth while navigating strategic initiatives. Modest Q1 2026 growth and strategic updates will moderately influence financial performance and investor sentiment.
11 May
Certara (CERT) released the transcript of its Q1 2026 earnings call detailing quarterly financial results, strategic updates, and future guidance. Q1 2026 earnings call transcript discloses financial performance and forward guidance directly shaping investor sentiment and stock trajectory.
Certara (CERT) shares slid after weak full-year guidance overshadowed a quarterly revenue beat. Weak full-year guidance signals potential financial headwinds, significantly altering investor sentiment and stock trajectory despite revenue beat.
Certara's Q1 earnings call highlights key financial results, strategic updates, and forward-looking guidance. Q1 earnings highlights disclose financial performance and outlook that significantly shape investor sentiment and company trajectory.
Certara, Inc. (CERT) reported first quarter 2026 financial results. Quarterly earnings reports significantly impact stock price, investor sentiment, and future guidance expectations.
Certara, Inc. (CERT) Q1 earnings missed analyst estimates. Q1 earnings miss will moderately impact financial performance and market sentiment.
7 May
Altasciences and Certara announce strategic partnership to accelerate early drug development through integrated biosimulation and preclinical services. Strategic partnership with Altasciences integrates Certara's biosimulation expertise into early drug development, enhancing revenue potential and competitive positioning.
5 May
Certara (CERT) sells its Regulatory and Medical Writing business to an undisclosed buyer for up to $135 million, including $100 million upfront and potential $35 million in milestones. Divestiture of non-core business for up to $135M provides significant cash proceeds and sharpens focus on biosimulation core operations.
27 Apr
Analysts revise price targets and expectations for Certara (CERT), signaling a shift in the company's investment narrative amid changing perceptions. Analyst revisions to targets and expectations moderately influence Certara's market sentiment and short-term performance trajectory.
22 Apr
Veristat will acquire Certara’s Regulatory and Medical Writing Business, enabling Certara to streamline operations and focus on its core biosimulation offerings. Divestiture of a key business unit is a major strategic move that refocuses Certara on core biosimulation while impacting revenue streams.
Certara enters definitive agreement to sell its Regulatory and Medical Writing business to Veristat. Divestiture of a business unit is a major strategic move that could refocus operations on core biosimulation and impact financials.
8 Apr
Certara (CERT) price targets reset lower by analysts as growth plans lag behind expectations, signaling an evolving company narrative amid underwhelming progress. Price target resets and lagging growth plans moderately impact Certara's financial performance and market sentiment without fundamentally altering its trajectory.
14 Mar
Certara's 2025 revenue met guidance, EBITDA margin topped the range, but Q4 software bookings slipped. Revenue hitting guidance and EBITDA exceeding range provide positives offset by slipping Q4 software bookings, yielding moderate overall financial impact.
13 Mar
Certara outlined its 2026 outlook at the Leerink Conference amid slowing software bookings and building AI initiatives. Slowing software bookings pose financial risks, but 2026 outlook and AI push represent major strategic moves altering trajectory and investor sentiment.
7 Mar
Certara CEO Resnick teased an upcoming decision on regulatory services and promoted the Phoenix Cloud platform at the TD Cowen Conference. CEO teases major regulatory services decision and cloud platform push, signaling significant strategic shifts.
3 Mar
Certara's Simcyp Simulator results have replaced ten human clinical trials for asciminib, a chronic myeloid leukemia therapy developed by Novartis, accelerating its approval and demonstrating the platform's predictive power in drug development. Validation of Simcyp replacing ten human trials for Novartis' asciminib highlights Certara's biosimulation technology's efficiency, likely driving adoption, partnerships, and revenue growth.
27 Feb
Certara, Inc. released Q4 2025 earnings call summary highlighting financial results, operational updates, and future outlook. Q4 earnings call summaries detail annual performance and guidance, often driving significant shifts in stock trajectory and investor confidence.
26 Feb
Certara Inc (CERT) Q4 2025 earnings call highlights navigating growth opportunities amid operational challenges. Q4 earnings highlights detail growth strategies and challenges poised to significantly shape Certara's future performance and investor sentiment.
Certara reported Q4 earnings call highlights, detailing financial performance, revenue growth, profitability metrics, strategic initiatives, and forward guidance. Q4 earnings highlights include key financial results and guidance that significantly shape investor expectations and stock trajectory.